insights_auto
Perspektīva: 37.0% garā pozīcija·17.8% īsā pozīcija
Pāriet uz analīzichevron_right
NVO:NYSE
Novo Nordisk A/S
43,24 $
arrow_upward
+0,12%(+0,050) 1 d.
43,34 $
arrow_upward
+0,23% (+0,100)bedtimePēctirdzniecības
Slēgts: 18. sept., 16:04:12 GMT-4 · USD
search
Visi simboli
1 d.
5 d.
1 m.
6 m.
Š.g.
1 g.
5 g.
Maks.
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: NVO…
Atvērt
43,50 $
Augsta
43,54 $
Zema
42,78 $
Tirgus kapitalizācija
145,43 mljrd.
Vid. apjoms
10,62 milj.
Apjoms
10,37 milj.
Dividende
4,15%
Ceturkšņa dividendes
0,45 $
Datums, kad tiek pārtraukta dividenžu izmaksa
2026. gada 14. aug.
Cenas/peļņas attiecība
10,76
Augstākā 52 ned.
64,16 $
Zemākā 52 ned.
35,12 $
Peļņa uz vienu akciju
4,02 $
Beta
0,73
Apgrozībā esošās akcijas
3,39 mljrd.
Darbinieku skaits
67 tūkst.
Atvērt
43,50 $
Augsta
43,54 $
Zema
42,78 $
Tirgus kapitalizācija
145,43 mljrd.
Vid. apjoms
10,62 milj.
Apjoms
10,37 milj.
Dividende
4,15%
Ceturkšņa dividendes
0,45 $
Datums, kad tiek pārtraukta dividenžu izmaksa
2026. gada 14. aug.
Cenas/peļņas attiecība
10,76
Augstākā 52 ned.
64,16 $
Zemākā 52 ned.
35,12 $
Peļņa uz vienu akciju
4,02 $
Beta
0,73
Apgrozībā esošās akcijas
3,39 mljrd.
Darbinieku skaits
67 tūkst.
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
Simply Wall Street
·
pirms 4 stundām
Novo Nordisk (NVO) Secures Key EU Panel Backing For Child Growth Drug
Foreign Policy Journal
·
pirms 9 stundām
Novo Nordisk (NYSE: NVO) CEO Mike Doustdar Says Company Must "Rethink" Obesity Strategy To Reclaim Ground From Eli Lilly
AD HOC NEWS
·
pirms 17 stundām
Novo Nordisk stock reacts to CHMP backing for FREHEMGO and Novo rebranding
Benzinga
·
pirms 1 dienas
Congressman Ditches Magnificent Seven Stocks for Consumer Staples: Here's What He Bought
Profils
Novo is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo is controlled by majority shareholder Novo Holdings A/S which holds approximately 28.1% of its shares and a majority of its voting shares.
Novo manufactures and markets pharmaceutical products and services, primarily diabetes and obesity medications and devices.
Novo employs more than 48,000 people globally, and markets its products in 168 countries. The corporation was created in 1989, through a merger of two Danish companies, which date back to the 1920s. Novo is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights, while spin-off company Novozymes was named fourth. It is a leader in the FTSE4Good Index, and the only European company in the top ten. Novo is the largest pharmaceutical company in Denmark. Wikipedia
Par “Novo Nordisk A/S”
ĢenerāldirektorsMaziar Mike Doustdar
Darbinieki66,7 tūkst.
Dibināšanas datums1923. gada 21. dec.
Galvenais birojsBagsværd, Galvaspilsētas reģions, Dānija
Sektors-
Tīmekļa vietnenovonordisk.com